中国卫生资源
中國衛生資源
중국위생자원
CHINESE HEALTH RESOURCES
2014年
1期
51-52
,共2页
吴旭伶%邹欣%徐永玲%张玮
吳旭伶%鄒訢%徐永玲%張瑋
오욱령%추흔%서영령%장위
原发性胆汁性肝硬化%抗线粒体抗体M2亚型%成本效益法%生命年价值
原髮性膽汁性肝硬化%抗線粒體抗體M2亞型%成本效益法%生命年價值
원발성담즙성간경화%항선립체항체M2아형%성본효익법%생명년개치
primary biliary cirrhosis%anti-mitochondrial antibody-M2%cost-benefit approach%life value
目的：通过在体检人群中筛查抗线粒体抗体M2亚型（anti-mitochondrial antibody-M2，AMA-M2）以期提高原发性胆汁性肝硬化（PBC）的检出率，并评估该指标普查的经济价值。方法：运用卫生经济学中的成本效益法，测算区域性及全国性通过AMA-M2筛查PBC患者的经济效益。结果：无论在直接的医疗成本还是生命年价值上，通过AMA-M2早期筛查PBC将对患者及社会带来巨大的经济效益。结论：将AMA-M2检测作为我国常规健康体检筛查指标是提高PBC检出率并降低治疗成本的重要途径。
目的：通過在體檢人群中篩查抗線粒體抗體M2亞型（anti-mitochondrial antibody-M2，AMA-M2）以期提高原髮性膽汁性肝硬化（PBC）的檢齣率，併評估該指標普查的經濟價值。方法：運用衛生經濟學中的成本效益法，測算區域性及全國性通過AMA-M2篩查PBC患者的經濟效益。結果：無論在直接的醫療成本還是生命年價值上，通過AMA-M2早期篩查PBC將對患者及社會帶來巨大的經濟效益。結論：將AMA-M2檢測作為我國常規健康體檢篩查指標是提高PBC檢齣率併降低治療成本的重要途徑。
목적：통과재체검인군중사사항선립체항체M2아형（anti-mitochondrial antibody-M2，AMA-M2）이기제고원발성담즙성간경화（PBC）적검출솔，병평고해지표보사적경제개치。방법：운용위생경제학중적성본효익법，측산구역성급전국성통과AMA-M2사사PBC환자적경제효익。결과：무론재직접적의료성본환시생명년개치상，통과AMA-M2조기사사PBC장대환자급사회대래거대적경제효익。결론：장AMA-M2검측작위아국상규건강체검사사지표시제고PBC검출솔병강저치료성본적중요도경。
Objective:To increase the detection rate of primary biliary cirrhosis(PBC)through testing anti-mitochondrial antibody-M2(AMA-M2)and to evaluate the economic value of the indication. Methods:Cost-effectiveness method was used to measure the economic value of screening PBC patients with AMA-M2 regionally and nationally. Results:Early screening of AMA-M2 in patients with PBC could bring extraordinary economic benefits to patients and the society from both direct medical costs and life value perspective. Conclusion:It is suggested that AMA-M2 should be enrolled as one of the routine indexes of health examination in China,which is an important way to increase PBC detection rate and decrease treatment cost.
